SCHEMBL31227628

SCHEMBL31227628

COc1ccc(F)c2c(N[C@@H]3CCCN(C(=O)OC(C)(C)C)C3)nccc12

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 2/20 0.44
▸ BTK Q06187 1/20 0.44
▸ POLB P06746 1/20 0.43
▸ CCNT1 O60563 2/20 0.42
▸ CDK9 P50750 2/20 0.42
▸ DNMT3A Q9Y6K1 1/20 0.42
▸ USP30 Q70CQ3 1/20 0.41
▸ GFER P55789 2/20 0.41
▸ EHMT2 Q96KQ7 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ ANO1 Q5XXA6 1/20 0.41
▸ HDAC4 P56524 1/20 0.41
▸ HDAC6 Q9UBN7 1/20 0.41
▸ SCN9A Q15858 1/20 0.41
▸ PDE4B Q07343 1/20 0.41
▸ NSD2 O96028 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31227853 0.90 PIK3CD (0.45) PIK3CDBTKUSP30GFEREHMT2
SCHEMBL31227178 0.87 PIK3CD (0.47) PIK3CDBTKCCNT1CDK9DNMT3A
SCHEMBL31227813 0.86 BTK (0.45) PIK3CDBTKUSP30GFERANO1
SCHEMBL31227369 0.85 PIK3CD (0.45) PIK3CDBTKPOLBCCNT1CDK9
SCHEMBL31227607 0.85 PIK3CD (0.47) PIK3CDBTKPOLBUSP30ANO1
SCHEMBL31227738 0.83 PIK3CD (0.47) PIK3CDBTKCCNT1CDK9USP30
SCHEMBL31227554 0.83 USP30 (0.48) PIK3CDBTKUSP30ANO1HDAC4
SCHEMBL31227331 0.82 BTK (0.44) PIK3CDBTKUSP30GFERANO1
SCHEMBL31227283 0.82 BTK (0.47) PIK3CDBTKUSP30GFERKMT2A
SCHEMBL21598992 0.81 USP30 (0.50) BTKPOLBUSP30HDAC4HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors INITIAL THERAPEUTICS, INC. (US) 2024-12-05 — — US disclosed
WO-2024226875-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS INITIAL THERAPEUTICS, INC. (US) 2024-10-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors MYCBP, MYC, MYCBP2 PIK3CD 3846/4885BTK 4542/4885POLB 849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback